SAB Biotherapeutics (SABS) Current Leases (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Current Leases data on file, last reported at $763705.0 in Q1 2026.

• Quarterly Current Leases rose 425.49% year-over-year to $763705.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $763705.0 (up 425.49% YoY) and the FY2025 annual result came in at $153967.0, up 8.0% from the prior year.
• Current Leases grew to $763705.0 in Q1 2026, from $153967.0 in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.2 million in Q1 2022 to a low of $127022.0 in Q2 2023.
• A 5-year average of $417098.4 and a median of $153967.0 in 2025 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases slumped 78.72% — and 2025, when it jumped 498.72%.
• Tracing SABS's Current Leases over 5 years: stood at $132788.0 in 2022, then jumped by 404.52% to $669946.0 in 2023, then tumbled by 78.72% to $142563.0 in 2024, then rose by 8.0% to $153967.0 in 2025, then surged by 396.02% to $763705.0 in 2026.
• The last three Current Leases figures came in at $763705.0 (Q1 2026), $153967.0 (Q4 2025), and $837286.0 (Q3 2025), per Business Quant data.